Cited 28 times in
Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 심효섭 | - |
dc.date.accessioned | 2020-09-29T01:41:29Z | - |
dc.date.available | 2020-09-29T01:41:29Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/179481 | - |
dc.description.abstract | Expression of immune checkpoint ligands (ICLs) is necessary to trigger the inhibitory signal via immune checkpoint receptors (ICRs) in exhausted T cells under tumor immune microenvironment. Nevertheless,to our knowledge, ICL expression profile in cancer patients has not been investigated. Using previously reported RNA-seq data sets, we found that expression of ICLs was patient specific but their coexpression can be patterned in non-small-cell lung cancers (NSCLCs). Since the expression of PD-L1 and poliovirus receptor (PVR) among various ICLs was independently regulated, we could stratify the patients who were treated with anti-PD-1 later into 4 groups according to the expression level of PD-L1 and PVR. Of interest, high PVR and low PVR expressions in PD-L1-expressing patients enriched nonresponders and responders to PD-1 blockade, respectively, helping in further selection of responders. Using a genetically engineered cancer model, we also found that PVR-deficient and PD-L1-sufficient tumor-bearing mice were highly sensitive to anti-PD-1 therapy, whereas PVR-sufficient and PD-L1-deficient tumor-bearing mice were resistant to anti-PD-1 therapy. Taken together, our study provides a concept that combinatorial expression patterns of PVR and PD-L1 are key determinants for PD-1 blockade and furthermore suggest a better therapeutic usage of immune checkpoint blockades (ICBs). | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | American Society for Clinical Investigation | - |
dc.relation.isPartOf | JCI INSIGHT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Bo Ryeong Lee | - |
dc.contributor.googleauthor | Sehyun Chae | - |
dc.contributor.googleauthor | Jihyun Moon | - |
dc.contributor.googleauthor | Myeong Joon Kim | - |
dc.contributor.googleauthor | Hankyu Lee | - |
dc.contributor.googleauthor | Hyuk Wan Ko | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Hyo Sup Shim | - |
dc.contributor.googleauthor | Daehee Hwang | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Sang-Jun Ha | - |
dc.identifier.doi | 10.1172/jci.insight.128633 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A02219 | - |
dc.relation.journalcode | J03720 | - |
dc.identifier.eissn | 2379-3708 | - |
dc.identifier.pmid | 32554931 | - |
dc.identifier.url | https://insight.jci.org/articles/view/128633 | - |
dc.subject.keyword | Cancer immunotherapy | - |
dc.subject.keyword | Immunology | - |
dc.subject.keyword | Oncology | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.contributor.affiliatedAuthor | 심효섭 | - |
dc.citation.volume | 5 | - |
dc.citation.number | 14 | - |
dc.citation.startPage | 128633 | - |
dc.identifier.bibliographicCitation | JCI INSIGHT, Vol.5(14) : 128633, 2020-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.